Abstract
NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohns disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.
Keywords: NGAL, acute renal failure, chronic kidney disease, clinical nephrology, clinical pharmacology, glomerulonephritis, vasculitis, antimicrobial, gentamicin, microalbuminuria, Crohn's disease, flogistic, Infliximab, idiopathic, streptozotocin, angiotensin, sepsis, inefficacy, etiologic, immunosuppressors
Current Pharmaceutical Design
Title: NGAL is a Precocious Marker of Therapeutic Response
Volume: 17 Issue: 8
Author(s): Valeria Cernaro, Davide Bolignano, Valentina Donato, Antonio Lacquaniti, Antoine Buemi, Eleonora Crascì, Silvia Lucisano and Michele Buemi
Affiliation:
Keywords: NGAL, acute renal failure, chronic kidney disease, clinical nephrology, clinical pharmacology, glomerulonephritis, vasculitis, antimicrobial, gentamicin, microalbuminuria, Crohn's disease, flogistic, Infliximab, idiopathic, streptozotocin, angiotensin, sepsis, inefficacy, etiologic, immunosuppressors
Abstract: NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohns disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.
Export Options
About this article
Cite this article as:
Cernaro Valeria, Bolignano Davide, Donato Valentina, Lacquaniti Antonio, Buemi Antoine, Crascì Eleonora, Lucisano Silvia and Buemi Michele, NGAL is a Precocious Marker of Therapeutic Response, Current Pharmaceutical Design 2011; 17 (8) . https://dx.doi.org/10.2174/138161211795428939
DOI https://dx.doi.org/10.2174/138161211795428939 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
STING Activation and its Application in Immuno-Oncology
Current Topics in Medicinal Chemistry Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging A Simple and Rapid Method for Expression and Purification of Functional TNF-α Using GST Fusion System
Current Pharmaceutical Biotechnology Comparative Analysis of the Rabbit Endothelial Progenitor Cells from Bone Marrow and Peripheral Blood Treated with Selenium Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy Platelet-neutrophil Interactions as a Target for Prevention and Treatment of Transfusion- related Acute Lung Injury
Current Pharmaceutical Design Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Quantitative Determination and Validation of Four Phenolic Acids in <i>Salvia Miltiorrhiza</i> Bunge using <sup>1</sup>H-NMR Spectroscopy
Current Pharmaceutical Analysis Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Hendra and Nipah Viruses: Pathogenesis and Therapeutics
Current Molecular Medicine The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design The Role of WNT in Rheumatoid Arthritis and its Therapeutic Implication
Mini-Reviews in Medicinal Chemistry Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design